

Washington University School of Medicine

Digital Commons@Becker

Open Access Publications

2018

Homozygous KSR1 deletion attenuates morbidity but does not prevent tumor development in a mouse model of RAS-driven pancreatic cancer

Elizabeth A. Germino

Washington University School of Medicine in St. Louis

Joseph P. Miller

Washington University School of Medicine in St. Louis

Lauri Diehl

Genentech, South San Francisco

Carter J. Swanson

Genentech, South San Francisco

Steffen Durinck

Genentech, South San Francisco

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation

Germino, Elizabeth A.; Miller, Joseph P.; Diehl, Lauri; Swanson, Carter J.; Durinck, Steffen; Modrusan, Zora; Miner, Jeffrey H.; and Shaw, Andrey S., "Homozygous KSR1 deletion attenuates morbidity but does not prevent tumor development in a mouse model of RAS-driven pancreatic cancer." PLoS One. 13, 3. e0194998. (2018).

https://digitalcommons.wustl.edu/open_access_pubs/6821

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors

Elizabeth A. Germino, Joseph P. Miller, Lauri Diehl, Carter J. Swanson, Steffen Durinck, Zora Modrusan, Jeffrey H. Miner, and Andrey S. Shaw


RESEARCH ARTICLE

Homozygous KSR1 deletion attenuates morbidity but does not prevent tumor development in a mouse model of RAS-driven pancreatic cancer

Elizabeth A. Germino^{1,2}, Joseph P. Miller³, Lauri Diehl⁴, Carter J. Swanson², Steffen Durinck^{5,6}, Zora Modrusan⁶, Jeffrey H. Miner³, Andrey S. Shaw^{1,2*}

1 Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America, **2** Department of Research Biology, Genentech, South San Francisco, California, United States of America, **3** Division of Nephrology, Washington University School of Medicine, St. Louis, Missouri, United States of America, **4** Department of Pathology, Genentech, South San Francisco, California, United States of America, **5** Department of Bioinformatics and Computational Biology, Genentech, South San Francisco, California, United States of America, **6** Department of Molecular Biology, Genentech, South San Francisco, California, United States of America

* shaw.andrey@gene.com



OPEN ACCESS

Citation: Germino EA, Miller JP, Diehl L, Swanson CJ, Durinck S, Modrusan Z, et al. (2018) Homozygous KSR1 deletion attenuates morbidity but does not prevent tumor development in a mouse model of RAS-driven pancreatic cancer. PLoS ONE 13(3): e0194998. <https://doi.org/10.1371/journal.pone.0194998>

Editor: Murray Korc, Indiana University School of Medicine, UNITED STATES

Received: September 8, 2017

Accepted: March 14, 2018

Published: March 29, 2018

Copyright: © 2018 Germino et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by the Howard Hughes Medical Institute to AS and by Genentech Inc. AS, LD, SD and ZM are employed by Genentech. EAG was supported by a fellowship from the Cancer Research Institute and from Genentech. Genentech provided support in the form of salaries for authors [EG, AS, CS, LD, SD,

Abstract

Given the frequency with which MAP kinase signaling is dysregulated in cancer, much effort has been focused on inhibiting RAS signaling for therapeutic benefit. KSR1, a pseudokinase that interacts with RAF, is a potential target; it was originally cloned in screens for suppressors of constitutively active RAS, and its deletion prevents RAS-mediated transformation of mouse embryonic fibroblasts. In this work, we used a genetically engineered mouse model of pancreatic cancer to assess whether KSR1 deletion would influence tumor development in the setting of oncogenic RAS. We found that *Ksr1*^{-/-} mice on this background had a modest but significant improvement in all-cause morbidity compared to *Ksr1*^{+/+} and *Ksr1*^{+/-} cohorts. *Ksr1*^{-/-} mice, however, still developed tumors, and precursor pancreatic intraepithelial neoplastic (PanIN) lesions were detected within a similar timeframe compared to *Ksr1*^{+/+} mice. No significant differences in pERK expression or in proliferation were noted. RNA sequencing also did not reveal any unique genetic signature in *Ksr1*^{-/-} tumors. Further studies will be needed to determine whether and in what settings KSR inhibition may be clinically useful.

Introduction

KSR was originally cloned in *Drosophila* and *C. elegans* in separate screens for loss of function mutations that suppressed a constitutively active RAS protein [1–3]. KSR shares high homology with the RAF family of kinases, but the mammalian form lacks a catalytic lysine and so it has been characterized as a pseudokinase. It is proposed to function as a scaffold for RAF, MEK and ERK [3–9]. There are two isoforms, KSR1 and KSR2; data compiled in the Human

ZM], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.

Competing interests: This study was partly supported by Genentech Inc., the employer of EG, LD, SD, CS and ZM. J.H.M. has received grants from Hoffmann-La Roche, Basel and RGD13, Inc., Boston; has provided consultation to Third Rock Ventures, Boston; and has received licensing fees from Eli Lilly, Indianapolis and Genentech, South San Francisco. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Protein Atlas indicates that KSR1 mRNA expression is more ubiquitous, while KSR2 is mainly expressed in the brain [10]. *Ksr1*^{-/-} mice are phenotypically normal but have modest defects in T cell activation and long-term associative memory formation [11, 12]. In a mouse model of breast cancer based on a viral oncogene, the absence of KSR1 results in reduced tumor frequency and progression [11].

Mouse embryonic fibroblasts derived from *Ksr1*^{-/-} mice exhibit a significant reduction in EGF- and TPA-induced MAPK activation [13] and importantly, KSR1 is required for RAS-induced transformation [14, 15]. Furthermore, in a v-Ha-ras mouse model of skin papilloma, KSR1 deletion attenuates papilloma formation [13]. Lastly, antisense oligonucleotides to KSR1 are able to reduce tumor growth of KRAS-dependent human pancreatic carcinoma xenografts in nude mice [16].

These data support a role for KSR1 in the context of RAS-driven tumor growth, but KSR1 deficiency has not yet been tested in a genetically engineered mouse model of constitutively active RAS. One well-studied mouse model of RAS-driven pancreatic cancer combines a conditional oncogenic KRAS allele induced by a pancreatic-specific Cre on the background of a loss of either the tumor suppressor p53 or INK4/ARF, (reviewed in [17, 18]). This model recapitulates the progression of histological lesions that characterize human pancreatic ductal adenocarcinoma [19]. In this work, we sought to establish whether KSR1 deletion could influence RAS-driven tumorigenesis *in vivo* using this mouse model of pancreatic ductal adenocarcinoma (PDAC).

Methods

Mice

Mouse strains used in this study were: *Ksr1*^{-/-} [11], *Pdx1-Cre* [19], *p53*^{flax/flax} [20], *LSL-Kras*^{G12D/+} [21]. Mice were maintained on a C57BL/6 background. All mouse experiments were conducted with prior approval of the Washington University Animal Care and Use Committee. Animals were kept in conventional animal facilities and monitored daily by trained husbandry staff. Weights were charted weekly. Criteria for a humane endpoint were chosen to minimize animal suffering and included any weight loss or gain outside expected physiologic changes, changes in physical appearance that could cause distress including the development of rectal prolapse or other anatomic abnormalities, and changes in behavior including signs of lethargy. When required, mice were euthanized with CO₂ according to Institutional Animal Care and Use Committee (IACUC) guidelines. Consistent with our intent to maintain a humane endpoint, tumor burden in sacrificed mice was always found to be less than 20mm. Although rare, mice that died before showing any signs of morbidity were analyzed with necropsy when possible. In these cases, tumor burden was never found to be more than 20mm.

Histology

Immediately after animal sacrifice, the whole pancreas plus any visible tumor was removed for histological analysis. To study the phenomenon of rectal prolapse, the gastrointestinal tract was removed from the duodenum to the rectum. Immunohistochemistry (IHC) was performed on formalin-fixed paraffin-embedded tissue sections mounted on glass slides. Multiple slides from each block were generated to reduce sampling error. All IHC steps were carried out on the Ventana Discovery XT (Ventana Medical Systems) autostainer. Stained slides were independently reviewed in blinded fashion by a pathologist (L.D.) to assess pattern and strength of staining. Primary antibodies: phospho-p44/42 MAPK (ERK1/2; Thr202/Tyr204, Cell Signaling Technology) and Ki67 (clone SP6, LabVision/Thermo Fisher) were used at the concentration of 1μg/mL and a 1:200 dilution, respectively. Phospho-p44/42 MAPK was

incubated on slides for 60 minutes at room temperature. Ki67 was incubated on slides for 32 minutes at 37°C. Ventana OmniMap anti-Rabbit HRP was used as the detection system.

Next-generation sequencing and RT-qPCR

Snap-frozen tumor samples were processed using the AllPrep DNA/RNA isolation kit (Qiagen) according to the manufacturer's protocol to extract both DNA and RNA. Tissue homogenization and lysis was performed with the TissueLyser II (Qiagen). Approximately 30mg of tissue sample was added to 600μL RLT buffer with a sterilized stainless steel bead (3mm diameter) in a 2mL safe-lock microcentrifuge tube, then quickly transferred to the TissueLyser for 2 minutes at 25 Hz. Lysate was centrifuged at maximum speed for 3 minutes. Supernatant was transferred to an AllPrep DNA spin column before proceeding to the AllPrep protocol. Clean-up for RNA samples was done using the RNEasy MinElute kit (Qiagen) according to the manufacturer's protocol.

Gene expression profiling with RNA-seq was done using a total of 19 tumor samples with the following genotypes: 9 *Ksr1*^{-/-} tumors, 7 *Ksr1*^{+/-} tumors and 3 *Ksr1*^{+/+} tumors. Quality control of samples was done to determine RNA quantity and quality prior to their processing by RNA-seq. The concentration of RNA samples was determined using NanoDrop 8000 (Thermo Fisher Scientific) and the integrity of RNA was determined by Fragment Analyzer (Advanced Analytical Technologies). 0.5μg of total RNA was used as an input material for library preparation using TruSeq RNA Sample Preparation Kit v2 (Illumina). Size of the libraries was confirmed using 4200 TapeStation and High Sensitivity D1K screen tape (Agilent Technologies) and their concentration was determined by qPCR based method using Library quantification kit (KAPA). The libraries were multiplexed and then sequenced on HiSeq4000 (Illumina) to generate ~30 million single end 50 base pair reads.

RNASeq reads were aligned to the human genome version GRCh38 using GSNAP. Expression counts per gene were obtained by counting the number of reads aligned concordantly within a pair and uniquely to each gene locus as defined by NCBI and Ensembl gene annotations and RefSeq mRNA sequences. Differential gene expression analysis was performed using edgeR.

RT-qPCR was performed on RNA extracted from 13 of the 19 tumor samples analyzed for RNASeq. RNA was reverse transcribed using Superscript III First-Strand Synthesis System for RT-PCR (Thermo Fisher Scientific) with a starting concentration of 500 ng of RNA and using Oligo(dT) primers. cDNA from colon, lung and ovary of C57BL/6 mice (Zyagen) was used as a positive control for KSR2 expression. qPCR was performed using Taqman Universal PCR Master Mix (Thermo Fisher Scientific) and Taqman primers Mm02745105_m1 (KSR2) and Mm01171435_gH (EEF2) with FAM-MGB dyes (Thermo Fisher Scientific) with 800ng starting cDNA. qPCR was performed on a Quant Studio 7 Flex (Thermo Fisher Scientific) using the $\Delta\Delta C_t$ method. All samples were run with 3 technical replicates on a single MicroAmp Optical 96-well Reaction Plate covered with Optical Adhesive Film (Thermo Fisher Scientific).

Statistical analysis

Prism (version 7; GraphPad) was used for analysis and graphing of survival cohorts and qPCR data. Kaplan-Meier survival statistics were calculated using the log-rank test. P values < 0.05 were considered statistically significant. For qPCR data, comparisons of mean ΔC_t for the gene of interest relative to a reference gene were made for each genotype, with individual tumor samples treated as biological replicates, using one-way ANOVA with Sidak correction for multiple comparisons.

Results

Ksr1^{-/-} mice on the p53 flox/wt background have a slight decrease in all-cause morbidity

Ksr1^{-/-} mice [11] were bred to the previously described PDAC model with *Pdx1-Cre*, *LSL-Kras*^{G12D/+} and *Trp53*^{flox/flox} [22] to generate mice that were homozygous and heterozygous for KSR1 on the background of p53 homozygous deletion and heterozygous expression of KRAS G12D. Since the *Ksr1* and *p53* genes are both on chromosome 11, about 3mB apart, we initially bred and identified recombinants between these two loci. Haematoxylin and eosin staining of the pancreas of *Pdx1-Cre;LSL-Kras*^{G12D/+}; *Trp53*^{flox/flox}; *Ksr1*^{-/-} mice sacrificed at several time points confirmed the presence of pancreatic ductal adenocarcinoma with tumors identified in all mice between 3–4 weeks of age. We suspected that the rapid onset and aggressiveness of tumors in this model might obscure more subtle differences between knockout and wild-type mice. We therefore generated animals with p53 heterozygosity instead of p53 homozygous deletion.

We generated *Ksr1*^{-/-}, *Ksr1*^{+/-}, and *Ksr1*^{+/+} cohorts on the *Pdx1-Cre;LSL-Kras*^{G12D/+}; *Trp53*^{flox/wt} background; unless otherwise stated, we use *Ksr1*^{-/-}, *Ksr1*^{+/-}, or *Ksr1*^{+/+} as shorthand to refer to these cohorts which always have the background genotype *Pdx1-Cre;LSL-Kras*^{G12D/+}; *Trp53*^{flox/wt}. Mice were followed weekly and sacrificed after changes in weight and/or signs of lethargy. Due to ethical concerns, mice were also sacrificed if they developed any other abnormality that might cause unnecessary suffering, including rectal prolapse. Ages of mice at sacrifice or death were plotted in a Kaplan-Meier survival curve (Fig 1). The difference in survival curves for *Ksr1*^{+/-} and *Ksr1*^{+/+} mice was not statistically significant (Fig 1A), and so they were grouped together to create one control group. When *Ksr1*^{-/-} mice were compared with *Ksr1*^{+/-} and *Ksr1*^{+/+} controls (Fig 1B), there was a modest but statistically significant decrease in all-cause morbidity (median age at sacrifice or death of 191 and 159 days respectively, $p = 0.0344$ by log-rank comparison). When segregated by gender, it was noted that the 4 of the 7 *Ksr1*^{-/-} mice sacrificed at 200 days or older mice were female, driving the overall *Ksr1*^{-/-} phenotype (S1 Fig). However, despite this trend the sample size was too small to detect a statistically significant difference between male and female mice. A more complete description of mice in these cohorts is included in S1 Table.

Ksr1^{-/-} mice develop PanIN lesions by 3 months of age

Because *Ksr1*^{-/-} mice had a modest improvement in overall morbidity, we investigated whether there might be a delay in the appearance of pre-cancerous pancreatic intraepithelial neoplasms (PanIN). We sacrificed a cohort of mice from each genotype (3 *Ksr1*^{+/+}, 3 *Ksr1*^{+/-}, and 9 *Ksr1*^{-/-}) at 12 weeks of age and prepared the pancreas for histological analysis. We observed characteristic noninvasive PanIN lesions, comprising columnar/cuboidal ductal epithelial cells with variable mucin, in all three groups of mice (Fig 2). There was no obvious difference in number or severity of lesions between the three groups of mice. Ductal cells in PanIN lesions for all groups were positive and similar in intensity for pERK staining. In all, there were no obvious differences in early tumor development in *Ksr1*^{-/-} mice compared to control animals in this PDAC model.

Ksr1^{-/-} mice still develop pancreatic ductal adenocarcinoma

While *Ksr1*^{-/-} mice were generally older before showing signs of morbidity compared to control animals, all mice eventually succumbed to pancreatic tumors. Histological analysis revealed that these tumors were ductal adenocarcinomas of similar grade to tumors examined




Fig 1. *Pdx1-Cre;LSL-Kras^{G12D/+};Trp53^{lox/wt};Ksr1^{-/-}* mice have a modest but statistically significant decrease in all-cause morbidity. A. Kaplan-Meier curves for *Pdx1-Cre;LSL-Kras^{G12D/+};Trp53^{lox/wt};Ksr1^{+/+}* and *Ksr1^{+/-}* mice based on age at sacrifice or death. 8 *Ksr1^{+/-}* and 10 *Ksr1^{+/+}* mice had to be censored. Median age at sacrifice or death was 152 days for *Ksr1^{+/-}* mice and 160 days for *Ksr1^{+/+}* mice; there was no statistically significant difference between the two groups ($p = 0.4683$ by log-rank test). B. Kaplan-Meier curves for *Pdx1-Cre;LSL-Kras^{G12D/+};Trp53^{lox/wt};Ksr1^{-/-}*, and *Ksr1^{+/+}* combined with *Ksr1^{+/-}* mice based on age at sacrifice or death. 3 *Ksr1^{-/-}* were censored. There was a modest but statistically significant difference between median age at sacrifice or death for *Ksr1^{-/-}* mice and the control group (191 and 159 days, $p = 0.0344$ by log-rank test).

<https://doi.org/10.1371/journal.pone.0194998.g001>

from *Ksr1^{+/+}* mice, with similar patterns and intensity of pERK and Ki67 staining (Fig 3). These results demonstrate that KSR1 deficiency does not prevent progression to aggressive PDAC in a KRAS-driven model with heterozygous loss of p53.

To test the possibility that a different cancer genetic signature emerged in the absence of KSR1, we compared gene expression by RNA sequencing (RNASeq). RNASeq showed that the samples were very heterogeneous with no common or distinct molecular signature in *Ksr1^{-/-}* tumors compared to tumors from *Ksr1^{+/+}* and *Ksr1^{+/-}* mice (S2A Fig). A subset of the *Ksr1^{-/-}* and *Ksr1^{+/-}* samples that did cluster together (2/9 *Ksr1^{-/-}* and 2/7 *Ksr1^{+/-}* tumors) yielded some




Fig 2. *Pdx1-Cre;LSL-Kras^{G12D/+};Trp53^{lox/wt};Ksr1^{-/-}* mice develop PanIN lesions at similar rates and severity to *Ksr1^{+/-}* and *Ksr1^{+/+}* mice. H&E staining of pancreatic tissues from *Pdx1-Cre;LSL-Kras^{G12D/+};Trp53^{lox/wt};Ksr1^{+/+}*, *Ksr1^{+/-}*, and *Ksr1^{-/-}* mice sacrificed at 3 months of age highlights PanIN lesions surrounded by normal tissue (bar = 40μm).

<https://doi.org/10.1371/journal.pone.0194998.g002>

statistically significant differences, including downregulation of glucagon and insulin in the *Ksr1^{-/-}* samples (S2B Fig). Therefore, expression analysis did not support a distinct genetic signature in *Ksr1^{-/-}* compared to *Ksr1^{+/-}* and *Ksr1^{+/+}* tumors. We specifically did not observe an upregulation in KSR2 message in *Ksr1^{-/-}* tumors. We further confirmed that there was not a relative increase in KSR2 with real-time quantitative PCR (RT-qPCR) using the same RNA samples (S3 Fig).

***Ksr1^{-/-}* animals are protected from rectal prolapse**

We noted that *Ksr1^{+/+}* and *Ksr1^{+/-}* on the PDAC background developed rectal prolapse at a relatively high frequency. 4/22 *Ksr1^{+/+}* and 7/17 *Ksr1^{+/-}* mice developed rectal prolapse and were sacrificed for that reason. Interestingly, none of the *Ksr1^{-/-}* mice (0/19) on the PDAC background developed rectal prolapse. This did not appear to correlate with tumor burden as the size or extent of tumor was not correlated with the presence or absence of rectal prolapse. As noted in S1 Table, more female *Ksr1^{-/-}* mice (6/12) were sacrificed due to rectal prolapse (compared to 1/5 males), while the trend was reversed for *Ksr1^{+/+}* mice (1/13 females compared to 3/9 males); however, it should be stressed that our sample size is too small to draw definite conclusions based on gender. Importantly, exclusion of all animals that developed rectal prolapse from our survival curves did not change the conclusion that *Ksr1* deficient animals had a modest increase in survival compared to the *Ksr1* wild-type and heterozygous animals.

Discussion

Given the frequency with which RAS is mutated in cancer, much effort has been focused on targeting RAS signaling for therapeutic benefit. KSR is a particularly attractive target because it is known to positively regulate MAPK signaling in the context of constitutively active RAS [1–3, 13–16, 23]. It also does not appear to be essential in normal cells, and so its inhibition might be expected to synergize with compounds that target other components of the MAP kinase signaling pathway without increasing toxicity. Indeed, one group has already reported a KSR-specific inhibitor that can synergize with the MEK inhibitor trametinib to decrease viability of RAS mutant cell lines [24]. Previously, we showed that KSR1 deficiency attenuated both the number and the growth of tumors that developed using the MMTV breast cancer model [11]. Another group used antisense oligonucleotides to demonstrate that KSR1 knockdown could




Fig 3. *Pdx1-Cre;LSL-Kras^{G12D/+};Trp53^{flax/wt};Ksr1^{-/-}* mice develop pancreatic tumors. H&E (top), pERK (middle) and Ki67 (bottom) staining of tumors harvested from *Pdx1-Cre;LSL-Kras^{G12D/+};Trp53^{flax/wt};Ksr1^{+/+}*, *Ksr1^{+/-}*, and *Ksr1^{-/-}* mice (bar = 100μm). Panels to the right show magnification of indicated region (bar = 40μm). Tumors have moderately differentiated ductal morphology that stains strongly for pERK, accompanied by stromal desmoplasia. Ki67 stains some ductal and surrounding cells.

<https://doi.org/10.1371/journal.pone.0194998.g003>

reduce growth of KRAS-dependent human pancreatic carcinoma xenografts in nude mice [16].

We therefore wanted to determine the effect of KSR1 deletion in a well-characterized mouse model of KRAS-driven pancreatic cancer. We found that the loss of KSR1 resulted in a modest, but statistically significant decrease in morbidity; however, all mice eventually succumbed to pancreatic tumors. This is somewhat surprising in light of previous work using antisense oligonucleotides [16], but our study is the first to test the role of KSR1 using this genetically engineered mouse model of PDAC. It is possible that the loss of KSR1 in the stromal or immune compartment could have compensated for the loss of KSR1 in tumor cells, or that KSR1 deletion caused developmental changes which circumvented KSR1 dependence for tumors in this particular model. It is also possible that this PDAC model is so robust that it masks a role for KSR1 which might be seen in other contexts of aberrant RAS signaling. Of note, our study incorporated KSR1 depletion in all tissues, while Xing *et al.* [16] used antisense oligonucleotides. Since the efficacy of KSR1 knockdown with antisense oligonucleotides correlates with cellular uptake and not with plasma levels [25], the effect of antisense oligonucleotides may have been greater in certain cells, including tumor cells, compared with other tissues, such as the immune compartment. Future studies using a KSR1 conditional knockout could help resolve some of these discrepancies. Notably, there may be important clinical distinctions between KSR1 knockdown, altering its conformation, and complete KSR1 deficiency, and so our results do not necessarily contradict efforts to target KSR1 for therapeutic benefit.

We can conclude that in this specific mouse model of pancreatic cancer, KSR1 signaling was not required for tumorigenesis. However, this does not rule out a role for KSR in other settings, especially in light of previous reports suggesting it is a positive regulator of RAS signaling [1–3, 11, 23, 26, 27]. In a study of human breast cancer where RAS mutations are rare, high KSR1 levels were shown to correlate with overall survival, and mechanistic studies suggested that this is due to KSR1 stabilization of BRCA1 [28]. KSR may therefore have functions outside of MAPK modulation that could impact cell growth and proliferation.

Of note, in our model we used a p53 deleted allele, while most genetically engineered PDAC mouse models use the p53 R172H hypomorph [29–33]. A previous study directly comparing heterozygous deletion of p53 to heterozygous expression of p53 R172H in the same PDAC model showed no difference in tumor latency or survival. However, 13/20 of hypomorphic p53 mutant mice had liver metastases compared to 0/20 of mice with the heterozygous p53 deletion [34]. Similarly, we rarely observed liver metastases in our mice, and it is therefore possible that using the deleted p53 allele might have masked a biological role of KSR1 in promoting p53-driven metastases.

One hypothesis is that KSR2 could be compensating for the absence of KSR1. We did not, however, detect KSR2 expression in the pancreas nor did we see it upregulated in the RNASeq analysis performed on *Ksr1*^{-/-} mouse tumors. We further confirmed with RT-qPCR that relative KSR2 expression did not increase in *Ksr1*^{-/-} compared to *Ksr1*^{+/+} tumor samples, and so a compensatory role for KSR2 is less likely. With RNASeq, we were also unable to detect a difference in genetic signature based on KSR1 genotype. While this could be consistent with the absence of a strong phenotypical difference between *Ksr1*^{-/-} and *Ksr1*^{+/+} mice, it may also reflect the heterogeneity of the tumors analyzed. All these caveats are important to keep in mind for future studies of KSR.

One unexpected finding that arose during the course of this study was a high frequency of rectal prolapse that occurred in the *Ksr1*^{+/+} and *Ksr1*^{+/-} cohorts (4/22 and 7/17 respectively). Because of ethical concerns, we were forced to sacrifice these mice at the time we noticed the prolapse. Prolapse did not correlate with the presence of gross tumor at sacrifice, nor with the size or extent of tumor. Importantly, removal of all animals with prolapse did not have any

significant effect on the overall survival statistics. We do not know why *Ksr1*^{-/-} mice were protected from the development of rectal prolapse, nor why its incidence has not been documented in other reports. One previous study did mention rectal prolapse in passing as a reason for censorship in survival analysis of *Pdx1-Cre;LSL-Kras*^{G12D/+};*Trp53*^{LSL-R172H/wt} mice [35]. It is possible that in our cohort, PDX1-Cre is expressed in cells in the intestine or that the absence of KSR1 in immune cells is causing a defect in the intestinal barrier through perhaps a change in the microbiome. Preliminary histology from a mouse with prolapse showed a mild to moderate enteritis in the small bowel with an inflammatory infiltrate and apoptotic cells throughout the intestinal crypts, as well as a mild increased inflammatory infiltrate in the colon. Our results suggest a protective effect in *Ksr1*^{-/-} mice that would be interesting to investigate in future studies.

Overall, the trend toward decreased morbidity with *Ksr1*^{-/-} mice that we observed was modest and all mice eventually developed invasive ductal adenocarcinoma. Even though our study does not point to an essential function for KSR1 in KRAS-driven pancreatic cancer with heterozygous loss of p53, we cannot rule out a supporting role for KSR1, or a function in other contexts, and further work will be needed to dissect the complexities of KSR signaling.

Supporting information

S1 Table. Characteristics of mice in survival cohort. Note that 7/17 *Ksr1*^{+/-} and 4/22 *Ksr1*^{+/+} mice had to be sacrificed due to the development of rectal prolapse. (DOCX)

S1 Fig. Kaplan-Meier curves for *Pdx1-Cre;LSL-Kras*^{G12D/+};*Trp53*^{fllox/wt};*Ksr1*^{-/-} mice versus *Pdx1-Cre;LSL-Kras*^{G12D/+};*Trp53*^{fllox/wt};*Ksr1*^{+/-} and *Ksr1*^{+/+} mice according to gender. While there was a trend toward *Ksr1*^{-/-} females sacrificed at an older age, given the sample size the difference is not statistically significant ($p = 0.0683$). There were also no other statistically significant differences between the different gender cohorts. (TIF)

S2 Fig. mRNA expression in tumors harvested from *Ksr1* cohorts do not cluster by genotype. A. Unsupervised clustering of mRNA expression across the entire transcriptome. *Ksr1* genotypes are indicated as KO (knockout), HET (heterozygous) and WT (wild-type). B. Two *Ksr1*^{-/-} and two *Ksr1*^{+/-} tumor samples were selected that each clustered based on whole transcriptome analysis. Depicted here are the top 100 candidates differentially expressed between the two genotypes. Four genes downregulated in *Ksr1*^{-/-} samples are listed with their respective p values (a complete list is included in S1 File). (TIF)

S3 Fig. Relative KSR2 expression does not increase in *Ksr1*^{-/-} compared to *Ksr1*^{+/+} tumor samples. RT-qPCR was performed on the same tumor RNA samples used for RNASeq. Δ CT values were calculated by subtracting KSR2 CT values from CT values for the reference gene, *EEF2*; accordingly, higher Δ CT values correspond to lower KSR2 expression. Each tumor sample is plotted as an individual point with error bars representing the standard deviation of the mean Δ CT for three technical replicates. Mean Δ CT values were not significantly different between 3 *Ksr1*^{+/+}, 5 *Ksr1*^{+/-}, and 5 *Ksr1*^{-/-} tumor samples (difference in Δ CT between *Ksr1*^{+/+} and *Ksr1*^{-/-}: -0.11, 95% confidence interval [CI] -2.92 to 2.71; between *Ksr1*^{+/-} and *Ksr1*^{-/-}: -0.52, 95% CI -2.96 to 1.92; between *Ksr1*^{+/+} and *Ksr1*^{+/-}: 0.41, 95% CI -2.40 to 3.23). RNA extracted from mouse colon, lung and ovary was used for positive controls. (TIF)

S1 File. Top 100 genes differentially expressed between the two *Ksr1*^{-/-} and two *Ksr1*^{+/-} tumor samples.
(XLSX)

Acknowledgments

The authors would like to acknowledge Melissa Junttila for helpful discussions and advice regarding the PDAC model, and Sharon Smith for expert administrative assistance.

Author Contributions

Conceptualization: Elizabeth A. Germino, Andrey S. Shaw.

Data curation: Elizabeth A. Germino, Jeffrey H. Miner.

Formal analysis: Elizabeth A. Germino.

Investigation: Elizabeth A. Germino, Joseph P. Miller, Lauri Diehl, Carter J. Swanson, Steffen Durinck, Zora Modrusan, Jeffrey H. Miner, Andrey S. Shaw.

Methodology: Elizabeth A. Germino.

Supervision: Andrey S. Shaw.

Writing – original draft: Elizabeth A. Germino.

Writing – review & editing: Elizabeth A. Germino, Andrey S. Shaw.

References

1. Kornfeld K, Hom DB, Horvitz HR. The *ksr-1* gene encodes a novel protein kinase involved in Ras-mediated signaling in *C. elegans*. *Cell*. 1995; 83(6):903–13. PMID: [8521514](#)
2. Sundaram M, Han M. The *C. elegans ksr-1* gene encodes a novel Raf-related kinase involved in Ras-mediated signal transduction. *Cell*. 1995; 83(6):889–901. PMID: [8521513](#)
3. Therrien M, Chang HC, Solomon NM, Karim FD, Wassarman DA, Rubin GM. KSR, a novel protein kinase required for RAS signal transduction. *Cell*. 1995; 83(6):879–88. PMID: [8521512](#)
4. Cacace AM, Michaud NR, Therrien M, Mathes K, Copeland T, Rubin GM, et al. Identification of constitutive and ras-inducible phosphorylation sites of KSR: implications for 14-3-3 binding, mitogen-activated protein kinase binding, and KSR overexpression. *Mol Cell Biol*. 1999; 19(1):229–40. PMID: [9858547](#)
5. Denouel-Galy A, Douville EM, Warne PH, Papin C, Laugier D, Calothy G, et al. Murine Ksr interacts with MEK and inhibits Ras-induced transformation. *Curr Biol*. 1998; 8(1):46–55. PMID: [9427625](#)
6. Kortum RL, Lewis RE. The molecular scaffold KSR1 regulates the proliferative and oncogenic potential of cells. *Molecular and cellular biology*. 2004; 24(10):4407–16. <https://doi.org/10.1128/MCB.24.10.4407-4416.2004> PMID: [15121859](#)
7. Stewart S, Sundaram M, Zhang Y, Lee J, Han M, Guan KL. Kinase suppressor of Ras forms a multiprotein signaling complex and modulates MEK localization. *Mol Cell Biol*. 1999; 19(8):5523–34. PMID: [10409742](#)
8. Xing H, Kornfeld K, Muslin AJ. The protein kinase KSR interacts with 14-3-3 protein and Raf. *Curr Biol*. 1997; 7(5):294–300. PMID: [9115393](#)
9. Yu W, Fantl WJ, Harrowe G, Williams LT. Regulation of the MAP kinase pathway by mammalian Ksr through direct interaction with MEK and ERK. *Curr Biol*. 1998; 8(1):56–64. PMID: [9427629](#)
10. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. *Science*. 2015; 347(6220):1260419. <https://doi.org/10.1126/science.1260419> PMID: [25613900](#)
11. Nguyen A, Burack WR, Stock JL, Kortum R, Chaika OV, Afkarian M, et al. Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivo. *Mol Cell Biol*. 2002; 22(9):3035–45. <https://doi.org/10.1128/MCB.22.9.3035-3045.2002> PMID: [11940661](#)

12. Shalin SC, Hernandez CM, Dougherty MK, Morrison DK, Sweatt JD. Kinase suppressor of Ras1 compartmentalizes hippocampal signal transduction and subserves synaptic plasticity and memory formation. *Neuron*. 2006; 50(5):765–79. <https://doi.org/10.1016/j.neuron.2006.04.029> PMID: 16731514
13. Lozano J, Xing R, Cai Z, Jensen HL, Trempus C, Mark W, et al. Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice. *Cancer Res*. 2003; 63(14):4232–8. PMID: 12874031
14. Hu J, Yu H, Kornev AP, Zhao J, Filbert EL, Taylor SS, et al. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. *Proc Natl Acad Sci U S A*. 2011; 108(15):6067–72. <https://doi.org/10.1073/pnas.1102554108> PMID: 21441104
15. Kortum RL, Johnson HJ, Costanzo DL, Volle DJ, Razidlo GL, Fusello AM, et al. The molecular scaffold kinase suppressor of Ras 1 is a modifier of RasV12-induced and replicative senescence. *Mol Cell Biol*. 2006; 26(6):2202–14. <https://doi.org/10.1128/MCB.26.6.2202-2214.2006> PMID: 16507997
16. Xing HR, Cordon-Cardo C, Deng X, Tong W, Campodonico L, Fuks Z, et al. Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer. *Nat Med*. 2003; 9(10):1266–8. <https://doi.org/10.1038/nm927> PMID: 12960962
17. Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L. Mouse models of pancreatic cancer. *World J Gastroenterol*. 2012; 18(12):1286–94. <https://doi.org/10.3748/wjg.v18.i12.1286> PMID: 22493542
18. Guerra C, Barbacid M. Genetically engineered mouse models of pancreatic adenocarcinoma. *Mol Oncol*. 2013; 7(2):232–47. <https://doi.org/10.1016/j.molonc.2013.02.002> PMID: 23506980
19. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell*. 2003; 4(6):437–50. PMID: 14706336
20. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. *Genes Dev*. 2000; 14(8):994–1004. PMID: 10783170
21. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. *Genes Dev*. 2001; 15(24):3243–8. <https://doi.org/10.1101/gad.943001> PMID: 11751630
22. Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, Hezel AF, et al. Both p16(Ink4a) and the p19 (Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. *Proc Natl Acad Sci U S A*. 2006; 103(15):5947–52. <https://doi.org/10.1073/pnas.0601273103> PMID: 16585505
23. Therrien M, Michaud NR, Rubin GM, Morrison DK. KSR modulates signal propagation within the MAPK cascade. *Genes Dev*. 1996; 10(21):2684–95. PMID: 8946910
24. Dhawan NS, Scopton AP, Dar AC. Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling. *Nature*. 2016; 537(7618):112–6. <https://doi.org/10.1038/nature19327> PMID: 27556948
25. Zhang J, Zafrullah M, Yang X, Yin X, Zhang Z, Fuks Z, et al. Downregulation of KSR1 in pancreatic cancer xenografts by antisense oligonucleotide correlates with tumor drug uptake. *Cancer Biol Ther*. 2008; 7(9):1490–5. PMID: 18719367
26. Muller J, Cacace AM, Lyons WE, McGill CB, Morrison DK. Identification of B-KSR1, a novel brain-specific isoform of KSR1 that functions in neuronal signaling. *Mol Cell Biol*. 2000; 20(15):5529–39. PMID: 10891492
27. Roy F, Laberge G, Douziech M, Ferland-McCollough D, Therrien M. KSR is a scaffold required for activation of the ERK/MAPK module. *Genes Dev*. 2002; 16(4):427–38. <https://doi.org/10.1101/gad.962902> PMID: 11850406
28. Stebbing J, Zhang H, Xu Y, Lit LC, Green AR, Grothey A, et al. KSR1 regulates BRCA1 degradation and inhibits breast cancer growth. *Oncogene*. 2015; 34(16):2103–14. <https://doi.org/10.1038/onc.2014.129> PMID: 24909178
29. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. *Cancer Cell*. 2005; 7(5):469–83. <https://doi.org/10.1016/j.ccr.2005.04.023> PMID: 15894267
30. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. *Science*. 2009; 324(5933):1457–61. <https://doi.org/10.1126/science.1171362> PMID: 19460966
31. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. *Cancer Cell*. 2012; 21(3):418–29. <https://doi.org/10.1016/j.ccr.2012.01.007> PMID: 22439937

32. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. *Science*. 2011; 331(6024):1612–6. <https://doi.org/10.1126/science.1198443> PMID: 21436454
33. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. *Gut*. 2013; 62(1):112–20. <https://doi.org/10.1136/gutjnl-2012-302529> PMID: 22466618
34. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. *Proc Natl Acad Sci U S A*. 2010; 107(1):246–51. <https://doi.org/10.1073/pnas.0908428107> PMID: 20018721
35. Evans RA, Diamond MS, Rech AJ, Chao T, Richardson MW, Lin JH, et al. Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. *JCI Insight*. 2016; 1(14).